pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

4,238 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1772Endpoints1378Fierce Biotech697BioSpace689BioPharma Dive522raps231onclive165fda recalls
therapy area
allOncology12282Rare Disease3185Immunology2860Cardiology2724Hematology2158Pulmonology2135Vaccines
  • Geriatrician urges careful use of AI predictions for older patients
    Artificial intelligence tools are being added to electronic health records to flag patients at risk for conditions such as sepsis, falls or even death. The ease of integration has led many clinicia…
    STAT · 1mo agoNeutral↗ source
  • Rise in Young Men Seeking Cosmetic Surgery Driven by Social Media Influence, Surgeon Observes
    A board‑certified plastic surgeon in Boston reports that more young men are now filling her waiting room than ever before, making men the fastest‑growing group in aesthetic procedures. Procedures…
    STAT · 1mo agoNeutral↗ source
← prev
page 57 of 170
next →
111
fda medwatch109
globenewswire health73
fda press59
1787
Psychiatry & CNS1200
Ophthalmology1047
Endocrinology & Metabolism775
Pain769
Nephrology758
FDA Approves First Gene Therapy for Pediatric Patients with Sanfilippo Syndrome Type A
The U.S. Food and Drug Administration today approved Fayuvi (rebisufligene etisparvovec-hopf), the first treatment for pediatric patients with mucopolysaccharidosis type IIIA (MPS IIIA), also known…
fda press · 1mo agoApprovalPositive↗ source
  • Novo Nordisk signs up to $1.4 billion deal with Orbis Medicines to develop oral macrocycle cardiometabolic drugs
    Novo Nordisk announced a partnership with Danish biotech Orbis Medicines, valued at up to $1.4 billion, to co-develop oral macrocycle drugs aimed at cardiometabolic diseases. The collaboration wil…
    BioSpace · 1mo agoDealPositive↗ source
  • Roche's Lunsumio clears Phase 3 hurdle, paving way for broader label in indolent lymphoma
    Roche announced that its T cell engager Lunsumio successfully met the primary endpoints in a Phase 3 study of a slow growing blood cancer. The trial, conducted in patients with indolent lymphoma,…
    Endpoints · 1mo agoPositive readoutPositive↗ source
  • Novartis' $12B Avidity deal falters as DM1 therapy misses Phase 3 endpoint
    Novartis' recent acquisition of Avidity Biosciences was intended to bring a novel therapy for Myotonic dystrophy type 1 (DM1) into its portfolio. The drug, del-desiran, an antibody-oligonucleotide…
    BioSpace · 1mo agoNegative readoutNegative↗ source
  • Orbis Medicines signs up to $1.4 billion partnership with Novo to develop macrocycle drugs for cardiometabolic disease
    Orbis Medicines, which is backed by Eli Lilly, announced a new collaboration with Novo focused on drug discovery. The agreement, valued at up to $1.4 billion, will target the creation of macrocycl…
    Endpoints · 1mo agoDealNeutral↗ source
  • England's NHS to fund AstraZeneca's Enhertu for metastatic breast cancer after U.K.-U.S. pricing pact
    English health authorities have agreed to provide AstraZeneca's breast cancer drug Enhertu through the NHS, ending a multi-year dispute over its availability. The decision will make the drug acces…
    STAT · 1mo agoDealPositive↗ source
  • FDA confronts surge of Chinese biotech firms as they become key industry players
    The FDA is currently assessing how to handle the rapid growth of biotech companies from China, which have moved from being economic competitors to important contributors in the pharmaceutical lands…
    Endpoints · 1mo agoRegulatoryNeutral↗ source
  • UK parliamentary committees demand probe into cost of US-UK pharma trade deal
    Six UK parliamentary committees have written to the relevant watchdog asking for an investigation into the cost of the United Kingdom's pharmaceutical trade agreement with the United States. The c…
    Endpoints · 1mo agoRegulatoryNegative↗ source
  • Michael J. Fox Foundation backs Ariadne Bio's non-hallucinogenic psychedelic for Parkinson's
    Ariadne Bio, a new biotech focused on Parkinson's disease, has received backing from the Michael J. Fox Foundation. The partnership centers on a non‑hallucinogenic psychedelic candidate that the fo…
    Endpoints · 1mo agoDealPositive↗ source
  • FDA staffing shortage limits ability to hire new employees, raising concerns for health-care oversight
    STAT's D.C. Diagnosis newsletter reports that the FDA is experiencing a staffing bottleneck, with too few current employees to bring on additional hires. The shortage could slow the agency's capac…
    STAT · 1mo agoRegulatoryNegative↗ source
  • Study finds purer fentanyl will not curb U.S. overdose deaths
    A new study highlighted that increasing the purity of fentanyl is unlikely to lower the number of overdose fatalities in the United States. Researchers noted that while purer fentanyl may be more…
    STAT · 1mo agoNegative↗ source
  • Biotech sector expected to weather Fed rate hike despite higher capital costs
    The Federal Reserve raised the federal funds rate by a quarter of a percentage point, a move that traditionally weighs on capital‑intensive industries like biotech. Analysts at BMO Capital Markets…
    BioSpace · 1mo agoRegulatoryPositive↗ source
  • Longeveron shares plunge 57% after stem-cell therapy fails in mid-stage heart trial
    Longeveron announced that its investigational stem cell product, laromestrocel, did not meet its primary endpoint in a Phase 2b study of infants with hypoplastic left heart syndrome (HLHS). The tri…
    BioSpace · 1mo agoNegative readoutNegative↗ source
  • Roche commits up to $1 billion to develop bispecific antibodies with Dualitas
    Roche announced a partnership with Dualitas Therapeutics, a California biotech, to advance bispecific antibody programs aimed at immunological and inflammatory diseases. The agreement includes an…
    BioSpace · 1mo agoDealPositive↗ source
  • Sellas’ Phase 3 REGAL AML Immunotherapy Study Delayed, Forecast to Miss Survival Endpoint
    Sellas Life Sciences Group’s experimental immunotherapy galinpepimut‑S (GPS) is being tested in a Phase 3 REGAL trial for patients with acute myeloid leukemia in a second remission. The study has b…
    STAT · 1mo agoNegative↗ source
  • Biopharma hiring surges in Massachusetts and California, with science/R&D and clinical roles leading demand
    BioSpace data shows that biopharma job postings on its site rose 17% between January and August 2026, signaling a broad increase in employment opportunities. Massachusetts and California dominate…
    BioSpace · 1mo agoNeutral↗ source
  • Researchers sue NIH over grant screening that they say violates First Amendment rights
    Researchers have filed a class action lawsuit against the National Institutes of Health, claiming the agency violates their First Amendment rights by searching grant applications for specific words…
    STAT · 1mo agoRegulatoryNegative↗ source
  • EU officials outline major pharmaceutical legislative reforms at RAPS Convergence 2026
    At RAPS Convergence 2026 in Charlotte, North Carolina, officials from the European Commission and the European Medicines Agency presented a set of reforms aimed at overhauling the European Union’s…
    raps · 1mo agoRegulatoryPositive↗ source
  • Bristol Myers ends $100M Phase 1 cancer ADC program
    Bristol Myers Squibb announced it has discontinued development of its Phase 1 antibody-drug conjugate candidate BMS-986497/ORM-6151. The decision follows a review of early clinical data, leading t…
    Endpoints · 1mo agoNegative↗ source
  • CMS offers Medicare pricing program exemptions to drugmakers who add Medicaid rebates
    The Centers for Medicare & Medicaid Services (CMS) has announced that drug manufacturers can be exempted from two Medicare pricing demonstration programs. The exemption is conditional on the compan…
    Endpoints · 1mo agoRegulatoryNeutral↗ source
  • Rare genetic variant linked to much higher lung cancer risk in never-smokers
    Researchers have discovered a very rare genetic variant that dramatically increases the odds of developing lung cancer among people who have never smoked. The study, published in Science, reports a…
    STAT · 1mo agoPositive↗ source
  • Cellares signs first Asian manufacturing deal with Taiwan's GenomeFrontier Therapeutics for CAR-T production
    Cellares announced a new partnership with Taiwanese biotech GenomeFrontier Therapeutics, marking the manufacturer’s first collaboration in Asia. The agreement will see Cellares evaluate and potenti…
    Endpoints · 1mo agoDealNeutral↗ source
  • Webinar Explores Manufacturing Risks and Partner Strategies for the Next Five Years
    The webinar titled "Manufacturing in Turbulent Times" is scheduled for September 17, 2026 and is designed to help biopharma sponsors understand the manufacturing challenges that lie ahead. It note…
    BioSpace · 1mo agoNeutral↗ source